Expansion and angiogenic potential of mesenchymal stem cells from patients with critical limb ischemia.

ABSTRACT:

Background

Critical limb ischemia (CLI) is a life- and limb-threatening condition affecting 1% to 10% of the population with peripheral arterial disease. Traditional revascularization options are not possible for up to 50% of CLI patients, in which case, the use of cellular therapies, such as bone marrow-derived mesenchymal stem cells (MSCs), hold great promise as an alternative revascularization therapy. However, no randomized, controlled phase 3 trials to date have demonstrated an improvement in limb salvage with cellular therapies. This may be due to poor cell quality (ie, inability to generate a sufficient number of angiogenic MSCs) or to the inadequate retention and viability of MSCs after delivery, or both. Because concerns remain about the expansion and angiogenic potential

SUBMITTER: Brewster L 

PROVIDER: S-EPMC4996777 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature